1-20 of 490
chronic lymphocytic leukemia refractory
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CLL-IPI: valid in the era of oral inhibitors?

Free
Nadine Kutsch
Journal: Blood
Blood (2021) 138 (2): 106–107.
https://doi.org/10.1182/blood.2021011937
Published: 2021
Journal Articles

Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia

Free
Clinical Trials & Observations
Carsten U. Niemann, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H. M. Mellink, Johan A. Dobber, Christian B. Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Mattias Mattsson, Mar Bellido, Hoa T. T. Tran, Kazem Nasserinejad, Arnon P. Kater
Journal: Blood
Blood (2021) 137 (8): 1117–1120.
https://doi.org/10.1182/blood.2020008608
Published: 2021
Includes: Supplemental data
Journal Articles

Occupy BTK: the key to controlling CLL

Free
Philip A. Thompson
Journal: Blood
Blood (2020) 136 (1): 4–6.
https://doi.org/10.1182/blood.2020005877
Published: 2020
Journal Articles

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Free
Clinical Trials & Observations
John C. Byrd, William G. Wierda, Anna Schuh, Stephen Devereux, Jorge M. Chaves, Jennifer R. Brown, Peter Hillmen, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline Barrientos, John M. Pagel, Jennifer A. Woyach, Kathleen Burke, Todd Covey, Michael Gulrajani, Ahmed Hamdy, Raquel Izumi, Melanie M. Frigault, Priti Patel, Wayne Rothbaum, Min Hui Wang, Susan O’Brien, Richard R. Furman
Journal: Blood
Blood (2020) 135 (15): 1204–1213.
https://doi.org/10.1182/blood.2018884940
Published: 2020
Includes: Supplemental data
Journal Articles

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Free
Jennifer R Brown, MD PhD, Kam Sprott, PhD, Santosh Reddy, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4312.
https://doi.org/10.1182/blood-2019-122491
Published: 2019
Journal Articles

T Cell Determinants of Response and Resistance to PD-1 Blockade in Richter's Transformation

Free
Erin Parry, MD PhD, Camilla K Lemvigh, MSc, Annabelle J Anandappa, MD, Shuqiang Li, PhD, Lillian Werner, MS, Ana Lako, Noelia Purroy, MD PhD, Satyen H Gohil, PhD, M.B.,B.S., Giacomo Oliveira, PhD, Pavan Bachireddy, MD, Teddy Huang, Ignaty Leshchiner, PhD, Aina Zurita Martinez, Lars Ronn Olsen, PhD, Kenneth Livak, PhD, Gad Getz, PhD, Donna S Neuberg, ScD, Scott J Rodig, MD PhD, William G. Wierda, MD PhD, Peter Kharchenko, PhD, Nitin Jain, MD, Catherine J. Wu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 680.
https://doi.org/10.1182/blood-2019-125904
Published: 2019
Journal Articles

Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor

Free
Anthony R. Mato, MDMSCE, Ian W. Flinn, MD PhD, John M. Pagel, MD PhD DSc, Jennifer R. Brown, MD PhD, Chan Y. Cheah, Catherine C. Coombs, MD, Manish R. Patel, MD, S. Michael Rothenberg, MD PhD, Donald E. Tsai, MD PhD, Nora C. Ku, MD, Michael L. Wang, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 501.
https://doi.org/10.1182/blood-2019-127509
Published: 2019
Journal Articles

Retrospective Non-Interventional Assessment of the Use of Idelalisib in Relapsed/Refractory Chronic Lymphocytic Leukemia Patients in Spain

Free
Christelle M Ferra, Manuel Perez Encinas, MD, Javier Lopez Jimenez, MD, Macarena Ortiz, MD, Santiago Osorio-Prendes, MD, Raul Cordoba, MD PhD, Angel Ramirez Payer, Eva González-Barca, MD PhD, Guillermo Martín Sánchez, MD, Marcos Gonzalez Diaz, MD, Maria Jose Sanchez, MD, Margarita Fernandez, MD, Patricia Baltasar Tello, MD, Elena Amutio, MD, María-Dolores García-Malo, MD, Maria Jesus Vidal Maceñido, MD, Pascual Fernandez, MD, Javier Loscertales, MD, Juan Nicolás Rodríguez, MD, Concha Alaez, MD, Heribert Ramroth, PhD, Margarida Palla
Journal: Blood
Blood (2019) 134 (Supplement_1): 5473.
https://doi.org/10.1182/blood-2019-126588
Published: 2019
Journal Articles

Phosphatidylinositol 3-Kinase (PI3K) Inhibitors-Related Hematological Toxicities in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

Free
Bradley J. Grant, JD, Anita Sultan, MD, Nicholas D'Cunha, MD, Chandler Graf, Sriman Swarup, MDMBBS, Myint Aung Win, MDMBBS, Ei Moe Phyu, MD, Thura Win Htut, MBBS, MRCP, Myat Min Han, MD, Yin Mon Myat, MD, Nimesh Adhikari, MD, Nyein Htway Yu, MBBS, MD, Donald P. Quick, MD, Kyaw Zin Thein, MDMBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 5877.
https://doi.org/10.1182/blood-2019-123531
Published: 2019
Journal Articles

Cost-Effectiveness of Venetoclax and Rituximab Combination Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in Argentina

Free
Jorge Federico Elgart, Economist, Mariana Glancszpigel, Economist, Diego Kanevsky, Biochemist, Maria Godar, BS, Valeria Touliet, Natalia Albaytero, Dentist
Journal: Blood
Blood (2019) 134 (Supplement_1): 2139.
https://doi.org/10.1182/blood-2019-121490
Published: 2019
Journal Articles

External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study

Free
Massimo Gentile, Fortunato Morabito, MD, Giovanni Del Poeta, MD, Francesca Romana Mauro, MD, Gianluigi Reda, MD, Paolo Sportoletti, Luca Laurenti, MD, Marta Coscia, MD PhD, Yair Herishanu, MD, Anna G Recchia, PhD BS, PharmD, Marzia Varettoni, Roberta Murru, MD, Annalisa Chiarenza, MD PhD, Adalgisa Condoluci, MD, Riccardo Moia, MD, Daniela Pietrasanta, MD, Giacomo Loseto, MD, Ugo Consoli, MD, Ilaria Scortechini, Francesca Maria Rossi, PhD, Antonella Zucchetto, Ernesto Vigna, MD, Giovanni Tripepi, Angela Rago, Ilaria Angeletti, Annalisa Biagi, MD, Ilaria Del Giudice, MD, Riccardo Bomben, PhD, Gian Matteo Rigolin, MD, Davide Rossi, MD PhD, Francesco Di Raimondo, MD, Gianluca Gaidano, MD PhD, Aaron Polliack, MD, Antonio Cuneo, MD, Robin Foà, MD, Valter Gattei, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4308.
https://doi.org/10.1182/blood-2019-126702
Published: 2019
Journal Articles

Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy

Free
Kristin Koenig, MD, Emily Dotson, PharmD, Shane Sheredy, Seema A. Bhat, MD, John C. Byrd, MD, Tracy Wiczer, Jennifer Woyach, MD, Farrukh T. Awan, MD, Kerry A. Rogers, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3045.
https://doi.org/10.1182/blood-2019-124538
Published: 2019
Journal Articles

A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (ONO/GS-4059) and Idelalisib with and without Obinutuzumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Free
Nadine Kutsch, MD, Christian Pallasch, Thomas Decker, Holger Hebart, Kai Uwe Chow, Ullrich Graeven, Jens Kisro, Alexander Kroeber, Eugen Tausch, Clemens-Martin Wendtner, Michael J. Eckart, Stephan Stilgenbauer, Xi Huang, Juliane M. Jürgensmeier, Pankaj Bhargava, Michael Hallek, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3047.
https://doi.org/10.1182/blood-2019-131025
Published: 2019
Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Free
Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3052.
https://doi.org/10.1182/blood-2019-130807
Published: 2019
Journal Articles

Obinutuzumab Alone or Combined with Chemotherapy in Previously Untreated (Fit or Unfit) or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients: Final Results from the Phase IIIb GREEN Safety Study with a Focus on Efficacy

Free
Stephan Stilgenbauer, MD, Francesc Bosch, MD PhD, Véronique Leblond, MD PhD, Osman Ilhan, MD, Jens Kisro, Béatrice Mahé, MD, Eva Mikuskova, MD PhD, Dzhelil Osmanov, MD, Gianluigi Reda, MD, Eugen Tausch, Marcin Wójtowicz, MD PhD, Thomas Perretti, MD MSc, Marlies EHM Van Hoef, MD PhD MBA, Robin Foà, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3035.
https://doi.org/10.1182/blood-2019-123419
Published: 2019
Journal Articles

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study

Free
Richard R. Furman, MD, William G. Wierda, MD PhD, Anna Schuh, Stephen Devereux, PhD, Jorge M. Chaves, MD, Jennifer R. Brown, MD PhD, Peter Hillmen, MD PhD, Peter Martin, FRCPC, MD MS, Farrukh T Awan, MD, Deborah M. Stephens, DO, Paolo Ghia, MD PhD, Jacqueline C. Barrientos, MD MS, John M. Pagel, MD PhD DSc, Jennifer Woyach, MD, Kathleen Burke, PhD, Todd Covey, Michael Gulrajani, Ahmed Hamdy, MD, Raquel Izumi, PhD, Melanie M. Frigault, PhD, Priti Patel, MD, Wayne Rothbaum, Min Hui Wang, PhD, Susan M. O'Brien, MD, John C. Byrd, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3039.
https://doi.org/10.1182/blood-2019-128706
Published: 2019
Journal Articles

The Dual PI3K-δ/γ Inhibitor Duvelisib in Combination with the Bcl-2 Inhibitor Venetoclax Shows Promising Responses in Richter Syndrome-PDX Models

Free
Andrea Iannello, PhD, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Elisa Marchi, Richard R. Furman, MD, John N. Allan, MD, Silvia Coma, PhD, Jonathan A. Pachter, PhD, Silvia Deaglio, MD PhD, Tiziana Vaisitti, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2862.
https://doi.org/10.1182/blood-2019-125754
Published: 2019
Journal Articles

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Free
Wei Xu, MD PhD, Yongping Song, Zengjun Li, Shenmiao Yang, Lihong Liu, Yu Hu, Wei Zhang, Jianfeng Zhou, Sujun Gao, PhD, Kaiyang Ding, Huilai Zhang, MD, Zunmin Zhu, MD, Shunqing Wang, Bing Xu, Jianda Hu, PhD, Ting Liu, MD, Chunyan Ji, Zhongjun Xia, MD, Yan Li, PhDMD, Xin Wang, MD PhD, Zhixin Xu, Renbin Zhao, Bin Zhang, PhD, Alan Zhu, Jianyong Li, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4319.
https://doi.org/10.1182/blood-2019-123331
Published: 2019
Journal Articles

Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor (CAR)-T Cell Therapy

Free
Merav Bar, MD, Julia Ruark, MD MPH, Erin Mullane, DNP, Nancy Cleary, BSc, Ana Cordeiro, MD, Evandro D. Bezerra, MD, Jenna M. Voutsinas, MPH, Bronwen E. Shaw, MD PhD, Qian Vicky Wu, PhD, Kathryn E Flynn, PhD, Stephanie J. Lee, MD MPH, Cameron J. Turtle, MBBS, PhD, David G. Maloney, MD PhD, Jesse Fann
Journal: Blood
Blood (2019) 134 (Supplement_1): 4453.
https://doi.org/10.1182/blood-2019-122755
Published: 2019
Journal Articles

Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells after Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data

Free
Rainer Boxhammer, Frank Striebel, Roland Baumgartner, Jan Endell
Journal: Blood
Blood (2019) 134 (Supplement_1): 5061.
https://doi.org/10.1182/blood-2019-128613
Published: 2019